National Breast Cancer Study of Epirubicin + CMF v Classical CMF Adjuvant Therapy
- Compare disease-free and overall survival of women with early stage breast cancer
treated with adjuvant cyclophosphamide, methotrexate, and fluorouracil with or without
- Compare the quality of life in a subgroup of these patients treated with these
OUTLINE: This is a randomized study. Patients are stratified according to radiotherapy
timing (concurrent versus sequential), nodal status (negative versus 1-3 versus at least 4),
age (50 and under versus over 50), grade, and tumor size. Patients are randomized to one of
two treatment arms.
- Arm I: Patients receive oral cyclophosphamide on days 1-14 and methotrexate IV and
fluorouracil IV on days 1 and 8. Treatment repeats every 4 weeks for 6 courses.
- Arm II: Patients receive epirubicin IV on day 1 every 3 weeks for 4 courses followed by
cyclophosphamide, methotrexate, and fluorouracil, as in arm I, for 4 courses.
Some patients may receive radiotherapy during or after chemotherapy. Treatment continues in
the absence of disease progression or unacceptable toxicity.
Quality of life is assessed in a subset of patients (N=500) before chemotherapy starts, at 3
months of treatment, at the end of chemotherapy, and at 6, 12, and 18 months after
Patients are followed annually for 10 years.
Peer Reviewed and Funded or Endorsed by Cancer Research UK
PROJECTED ACCRUAL: Approximately 2,000 patients will be accrued for this study within 4
Allocation: Randomized, Primary Purpose: Treatment
Helena Earl, MBBS, PhD, FRCP
Cambridge University Hospitals NHS Foundation Trust
United States: Federal Government